Paroxetine for Hot Flashes: Evidence, Dosing, and the Tamoxifen Caution

Paroxetine eases hot flashes by steadying the brain's temperature control, not by replacing hormones. As an SSRI, it raises serotonin signaling in the brain. Serotonin and the related chemical norepinephrine help set the body's internal thermostat in the hypothalamus.

At menopause, falling estrogen narrows the temperature range the body tolerates before it triggers a cooling response. Small shifts that once passed unnoticed now set off the flush and sweat of a hot flash. By raising serotonin signaling, paroxetine appears to widen that range again, so fewer triggers cross the threshold. This is a different mechanism from hormone therapy, which is why paroxetine can help women who cannot take estrogen. You can read more about how these drugs fit together in non-hormonal hot flash treatment.

Paroxetine 7.5 mg was the first non-hormonal drug the FDA ever approved for menopausal hot flashes. The agency cleared it on June 28, 2013, under the brand name Brisdelle, for moderate to severe vasomotor symptoms of menopause. Until then, every FDA-approved treatment for hot flashes contained estrogen, alone or with a progestin.

The molecule itself is old. Paroxetine was first approved in 1992 at higher doses to treat depression and anxiety. The 2013 approval was for a new low-dose 7.5 mg product aimed only at hot flashes, well below the antidepressant range.

Here is the part that matters for treatment today. The Brisdelle brand has been discontinued, so the dedicated 7.5 mg product is no longer sold. Low-dose paroxetine for hot flashes now uses generic paroxetine instead. Because the generic is approved for depression and anxiety rather than hot flashes, using it for vasomotor symptoms is off-label, even though a 7.5 mg product once carried that specific approval. The evidence behind it is the same; the regulatory label on the pill a woman actually fills is not.

Two large trials support low-dose paroxetine for hot flashes. Simon and colleagues ran two phase 3 studies, lasting 12 and 24 weeks, that randomly assigned 1,184 postmenopausal women to paroxetine 7.5 mg once daily or placebo (Simon 2013). Both compared the change in how often and how severe the hot flashes were.

Paroxetine beat placebo. It cut the weekly frequency of moderate to severe hot flashes more than placebo as early as week 4 and again at week 12, and the 24-week study confirmed that the benefit held over time. The reduction in severity also favored paroxetine. The effect is real but moderate, in line with the other non-hormonal options and smaller than what hormone therapy delivers.

Professional guidelines back this up. The Menopause Society's 2023 position statement on non-hormonal treatment recommends SSRIs and SNRIs, the class paroxetine belongs to, as evidence-based options for hot flashes when hormones are not used (NAMS 2023). Paroxetine is the one member of that group with its own FDA approval history for the indication.

The dose for hot flashes is 7.5 mg once daily, taken at bedtime. This is well below the 20 mg or higher daily doses used to treat depression, and the lower dose is part of why the side effect burden is lighter when paroxetine is used for hot flashes.

Relief builds over a few weeks rather than overnight. In the trials, the difference from placebo was already measurable by week 4. Bedtime dosing is deliberate, since taking it at night can blunt early nausea and may help with the sleep disruption that hot flashes cause.

Paroxetine should not be stopped abruptly. Doing so can bring on withdrawal symptoms such as dizziness, nausea, and a flu-like feeling. When it is time to stop, the dose is lowered gradually under a clinician's guidance.

Paroxetine should generally be avoided in women taking tamoxifen, and this is the main reason it is a second choice rather than a first on a non-hormonal pathway. Tamoxifen is a common breast cancer drug, and the body has to convert it into an active form using a liver enzyme called CYP2D6. Paroxetine is a strong inhibitor of that exact enzyme, so it can blunt the conversion and weaken tamoxifen's effect.

This is not a theoretical worry. A study of 2,430 women on tamoxifen found that those who also took paroxetine for longer stretches of their treatment had a higher risk of dying from breast cancer, while other antidepressants showed no such link (Kelly 2010). Because the women most likely to want a non-hormonal hot flash treatment are often the same women taking tamoxifen after breast cancer, this interaction carries real weight.

For these women, clinicians usually choose a different drug. Venlafaxine, an SNRI, has little effect on CYP2D6 and is a common alternative when tamoxifen is in the picture. The choice of a non-hormonal treatment after breast cancer is covered in hot flashes after breast cancer and in the broader guide to options when you can't take estrogen.

Most women tolerate low-dose paroxetine well, and the trials reported mostly mild to moderate side effects. The common ones are nausea, tiredness or sleepiness, dizziness, and dry mouth. These tend to ease over the first weeks, and bedtime dosing helps with several of them.

A few cautions apply to the SSRI class. Paroxetine should not be combined with an MAOI antidepressant, or with thioridazine or pimozide, because of dangerous interactions. Combining it with other drugs that raise serotonin can, rarely, cause serotonin syndrome, so the full medication list matters. SSRIs also carry a class warning about suicidal thoughts, mainly in younger adults, which is why any new mood changes should be reported.

The single most important safety point remains the tamoxifen interaction above. For a woman not taking tamoxifen or other CYP2D6-sensitive drugs, low-dose paroxetine is a reasonable non-hormonal option. For a woman who is, it is usually the wrong one, and a clinician will steer toward an alternative.